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Background: B-cell acute lymphoblastic leukemia (B-ALL) is the most common malignancy in pediatric patients
and the leading cause of cancer-related death in children and young adults. Translocations of 9p24 involving JAK2
(9p24) and gain-of-function mutations of JAK2 with subsequent activation of the JAK2 kinase have been described
in several hematological malignancies including B-ALL. However, rearrangements involving JAK2 are rare in B-ALL as
only few cases have been described in the literature.
Findings: Herein, we present a case of pediatric B-ALL whose conventional cytogenetics revealed an abnormal
karyotype with a reciprocal translocation involving 9p24 (JAK2) and 12p11.2. Fluorescence in situ hybridization (FISH)
studies using the RP11-927H16 Spectrum Green JAK2 probe on previously G-banded metaphases confirmed the
involvement of JAK2 in this rearrangement. Further FISH studies on the same previously G-banded metaphases
using the LSI MLL probe helped to characterize an insertion of MLL into 6q27 as an additional abnormality in this
karyotype. FISH studies performed on interphase nuclei also revealed an abnormal clone with MLL rearrangements
in 23.6% of the nuclei examined as well as an abnormal clonal population with a deletion of the 5'IGH@ region in
88.3% of the nuclei examined.
Conclusions: Rearrangements of 9p24 can result in constitutive activation of JAK2, and have been observed in
B-ALL. Rearrangements of the MLL gene have also been described extensively in B-ALL. However, rearrangements
of MLL with a partner at 6q27 and in conjunction with a translocation involving JAK2 have not been previously
described. This case pinpoints the importance of FISH and conventional cytogenetics to characterize complex
rearrangements in which JAK2 and MLL are involved. The therapeutic targeting of JAK2 and MLL in cases like this
may be prognostically beneficial.
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Abnormalities involving JAK2 (9p24) have been seen in
B-ALL, but most often via point mutations involving
the pseudokinase domain, R683 [1,2]. Rearrangements of
9p24, however, are rare, with only a small number of cases
reported in the literature involving the following loci and
partner genes: 22q11.2 (unknown gene), 12p13 (ETV6),
5p14.1 (SSBP2), 8p22 (PCM1), and 9p13.2 (PAX5) [1,3].
Activation of JAK2 occurs via gene fusions encoding
chimeric proteins in which the kinase domain of JAK2 is
fused to another cellular gene that provides a dimerization
or oligomerization interface to the JAK2 kinase domain,
leading to constitutive activation [1-5]. This case pinpoints
the fact that JAK2 rearrangements may play an important
role in the pathogenesis of lymphoblastic leukemias. To
the best of our knowledge, this is one of the few cases with
rearrangements of JAK2 with chromosome 12p11.2 as well
as rearrangements of MLL involving chromosome 6q27,
both with unknown partner genes.
Case presentation
A 13-year-old male presented with abdominal pain and fe-
vers for three months. He was found to have leukocytosis
(WBC 76.5x103/uL), anemia (Hgb 5.3 g/dL), and throm-
bocytopenia (platelet count 15.3x103/uL). Flow cytometry
on peripheral blood revealed 94% blasts which expressed
bright CD10, CD19, partial CD20, CD34, partial CD38,
partial TdT, CD79a, and HLA-DR. A bone marrow biopsy
showed a hypercellular marrow extensively involved
(~95%) by sheets of lymphoblasts. These findings are con-
sistent with a diagnosis of B-lymphoblastic leukemia. TheFigure 1 Abnormal karyotype seen on G-banded chromosomes in the
(p24;p11.2)[5]/46,XY[15].patient was immediately started on induction chemother-
apy with AALL0232 high-risk ALL chemotherapy proto-
col. A follow-up bone marrow biopsy on day 29 showed
minimal residual disease (MRD). A normal karyotype was
seen in all metaphase cells examined and loss of one copy
of the 5′IGH@ was the only abnormality detected in 2.7%
of the interphase nuclei studied. The patient subsequently
was given treatment per clinical trial AALL0031 and
achieved primary remission. Most recently, the patient re-
ceived a successful allogeneic bone marrow transplant
from a female donor.
Methods
Cytogenetics
Chromosome analysis was performed using standard
cytogenetic techniques on bone marrow and peripheral
blood, analyzing 20 metaphase cells. Karyotypes were
prepared using Applied Imaging CytoVision software
2013 nomenclature [6].
FISH
Fluorescence in situ hybridization (FISH) was performed
on interphase nuclei and previously G-banded metaphases
using the RP11-927H16 Spectrum Green JAK2 probe
(Empire Genomics, 700 Michigan Ave, suite 200, Buffalo,
NY 14203) and the following probes: Vysis LSI MLL Dual
Color Break Apart Probe, Vysis LSI ETV6 Dual Color
Break Apart, Vysis LSI ETV6(TEL)/RUNX1(AML1) ES
Dual Color Translocation Probe Set and Vysis LSI IGH
Dual Color, Break Apart Rearrangement Probe from
Abbott Molecular (Des Plaines, Illinois 60018).bone marrow: 46,XY,ins(6;11)(q27;q23q23),t(9;12),
Figure 2 Split MLL signals elucidated by FISH on interphase nuclei.
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Cytogenetics
Chromosome analysis of the bone marrow showed 5 of
20 cells with an MLL insertion on 6q27 as well as a bal-
anced translocation between 9p24 and 12p11.2 (Figure 1).
The same abnormalities were seen on a karyotype per-
formed on peripheral blood, though at a lower frequency
(1 of 20 cells).
In light of the FISH findings the karyotype of the bone
marrow of this patient was described as: 46,XY,ins(6;11)
(q27;q23q23),t(9;12),(p24;p11.2)[5]/46,XY[15].Figure 3 MLL insertion on 6q27 elucidated by FISH on previously G-bFISH
FISH analysis using interphase nuclei showed MLL split
signals in 23.6% (71/300) of the nuclei examined, suggestive
of an MLL (11q23) gene rearrangement (Figure 2). How-
ever, FISH performed on previously G-banded metaphases
also helped to identify two separate clonal populations with
different MLL abnormalities: one with an MLL rearrange-
ment mentioned above and one with an MLL insertion on
chromosome 6q27 (Figure 3). Additionally, a deletion of
the 5′ IGH@ region, corresponding to the variable segment
of the IGH@ was seen in 88.3% (265/300) of the nucleianded metaphase chromosomes.
Figure 4 Deletion of 5′ IGH@ elucidated by FISH on interphase nuclei.
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unbalanced rearrangement involving chromosome 14q32
(Figure 4).
FISH using the BAC RP11-927H16 probe (JAK2) showed
a JAK2 signal on the normal copy of chromosome 9, a
JAK2 signal on the short arm of chromosome 12, and a
JAK2 signal on the derivative chromosome 9 (Figure 5). Be-
cause there were no abnormalities involving ETV6 (12p13),
confirmed by using the Vysis LSI ETV6(TEL)/RUNX1
(AML1) ES Dual Color Translocation Probe Set on inter-
phase cells (Figures 6) and the Vysis LSI ETV6 Dual Color
Break Apart on metaphase cells (Figure 7), the breakpoints
on chromosome 12 were defined as 12p11.2 (Figure 7).Figure 5 FISH on metaphases using the BAC RP11-927H16
(JAK2) showed a signal on the normal copy of chromosome 9,
a JAK2 signal on the short arm of chromosome 12, and a JAK2
signal on the derivative chromosome 9.The constellation of these results was described as:
nuc ish(MLLx2)(5′MLL sep 3′MLLx1)[71/300].
nuc ish(ETV6,RUNX1)x2[300] .ish (5′ETV6,3′ETV6)x2
(5′ETV6 con 3′ETV6x2).
nuc ish(3′IGH@x2,5′IGHx1) (3xIGH@con 5′IGH@x1)
[265/300].
Discussion
The findings in this case - MLL rearrangements,
abnormalities of the IGH@, 12p abnormalities, and rear-
rangements of 9p24 involving the JAK2 locus - have
been previously described in B-ALL [1-3]. Abnormalities
involving IGH@ have only been recently identified as a
biologically and clinically relevant sub-group of B-ALL
[7]. However deletions of the 5′ IGH@ region have not
been well characterized in B-ALL in conjunction with
JAK2 rearrangements and MLL abnormalities. JAK2
translocations have been reported in B-ALL, although at
low frequencies. These B-ALL patients are most often
male, present with hyperleukocytosis, respond poorly to
chemotherapy, often relapse, and tend to have little to no
cytogenetic abnormalities apart from those involving JAK2
[1]. This fact may suggest that JAK2 rearrangements play a
driving role in the leukemogenesis of B-ALL.
JAK2 translocations induce dimerization or oligo-
merization of JAK2 without ligand binding, resulting in
constitutive activation of JAK2-mediated tyrosine kinase
pathways. It has been speculated that other cytogenetic
abnormalities occurring in conjunction with JAK2 rear-
rangements in B-ALL may recruit other altered tyrosine
kinase pathways that in turn, lead to an inferior clinical
outcome. A correlation has also been observed between
Figure 6 There was no evidence of ETV6/RUNX1 translocation by interphase FISH.
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and JAK2 mutations, most likely because CRLF2 is a JAK-
binding, Box 1 motif-containing cytokine receptor. In-
creased expression of CRLF2 independently has been
correlated with a poor prognosis in B-ALL, and the syner-
gistic effects of CRLF2 overexpression and JAK2 constitutive
activation may play a major role in the leukemogenesis of
the disease that can be prognostically considered and
therapeutically targeted [8]. Similarly, even point muta-
tions and rearrangements in the CRFL2 gene have been
reported to activate aberrant JAK2 signaling [9].
While JAK2 translocations are not common in lym-
phoblastic leukemia, it is clear that newly developedFigure 7 There was no evidence of ETV6 rearrangements by metaphasmall molecular JAK2 inhibitors such as TG101348 and
TG10129 developed by TargetGen, Inc. show promising
results in blocking the action of mutated JAK2 in myelo-
proliferative disorders [2,10]. There are at least 10 differ-
ent JAK inhibitors undergoing various phases of clinical
trials [11] including a group of TKIs used for both
MPDs and non-MPDs, namely MK-0457 (previously
VX-680), that has had JAK2 inhibitory action in MPD
and reduced kinase activity in T315I-positive ALL and
CML [2]. Lestaurtinib I(CEP-701), used mainly for mye-
loid malignancies, has also been used in a clinical trial to
treat children with B-ALL [11]. However, among neo-
plasias dependent on tyrosine kinases, treatment withse FISH.
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velopment of inhibitor resistance mutations [9]. A novel
JAK2 inhibitor, NVP_BVB808 (BVB808), has been used
experimentally in mice xenografted with human B-ALL to
recover E864K, Y931C, and G935R mutations within the
kinase domain of JAK2 that confer resistance to mul-
tiple JAK2 enzymatic inhibitors [9]. In addition, treat-
ment with inhibitors of heat shock protein 90 (HSP90)
has now been used experimentally to overcome all three
resistance mutations and potentially kill cells dependent
on JAK2. However, development of new therapies that
target the abnormal JAK2 tyrosine kinase activity may
benefit patients diagnosed with ALL presenting with
JAK2 rearrangements [9].
Structural abnormalities involving the MLL gene (11q23)
with various partner genes have been reported in ALL
in ~6% of cases, but an MLL insertion at 6q27 has not
been reported to the best of our knowledge [12]. Herein,
conventional and molecular cytogenetic metaphase
analysis solely revealed an insertion of MLL on chromo-
some 6q27 with an unknown fusion partner gene; how-
ever, further molecular cytogenetic studies on interphase
nuclei unveiled a second clonal population of cells harbor-
ing an MLL rearrangement. Inversion of MLL may, how-
ever, have followed rearrangements with chromosome 6
(as opposed to preceding it). Limited sample material
prevented further molecular characterization. Further-
more, MLL insertions have been reported to result in
chimeric fusion genes and are usually associated with a
poor prognosis [3,12].
In short, our case highlights the importance of using
multiple tools, namely conventional cytogenetic and mo-
lecular genetic analysis, to elucidate complex rearrange-
ments involving JAK2 and MLL genes. The detection
and therapeutic targeting of MLL as well as JAK2 abnor-
malities in cases of ALL may be prognostically beneficial
as they may represent a distinct subtype of acute
lymphoblastic leukemia. To the best of our knowledge,
this study is the first reported case of a pediatric B-ALL
that shows a concurrent MLL gene rearrangement with
a JAK2 translocation and deletion of the 5′ IGH@ re-
gion. This case sheds light on the potential significance
of JAK2 and MLL as prognostic and therapeutic targets
in lymphoblastic leukemias, and suggests further investi-
gation to determine the benefits of the newly developed
JAK2 inhibitors against translocations involving JAK2 in
pediatric B-ALL.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CAT led the entire writing of the manuscript. DS wrote the first draft,
conducted a survey for relevant literature, and edited and revised future
drafts. MDN contributed with the discussion and reviewed the manuscript.
RG edited the manuscript and helped to organize the figures. DRcontributed with the clinical history. LY conducted all the cytogenetics, FISH,
and bench work and interpretation of the results. NR edited and revised the
final draft. All authors read and approved the final manuscript.
Acknowledgement
To Dr. Christopher Kim for helping with the clinical history of this
manuscript.
Author details
1Department of Pathology and Laboratory Medicine, David Geffen UCLA
School of Medicine, Los Angeles, CA 90095, USA. 2Department of
Microbiology, Immunology, and Molecular Genetics, UCLA, Los Angeles, CA
90095, USA. 3UT Southwestern Medical Center Department of Pathology,
Dallas, Texas, USA.
Received: 7 November 2013 Accepted: 8 November 2013
Published: 25 November 2013
References
1. Tirado CA, et al: Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2)
in B-acute lymphoblastic leukemia. Leuk Res 2010, 34(12):1674–1676.
2. Ho K, et al: JAK2 translocations in hematological malignancies: review of
the literature. J Assoc Genet Technol 2010, 36(3):107–109.
3. Lacronique V, Boureux A, Valle VD, et al: A TEL-JAK2 fusion protein with
constitutive kinase activity in human leukemia. Science 1997, 278:1309–1312.
4. Mullighan CG, et al: JAK mutations in high-risk childhood acute
lymphoblastic leukemia. Proc Natl Acad Sci USA 2009, 106:9414–9418.
5. Smith CA, Fan G: The sage of JAK2 mutations and translocations in
hematologic disorders: pathogenesis, diagnostic and therapeutic
prospects, and revised World Health Organization diagnostic criteria for
myeloproliferative neoplasms. Hum Pathol 2008, 39:795–810.
6. Shaffer LG, McGowan-Jordan J, Schmid MS: ISCN 2013: An International
System of Human Cytogenetic Nomenclature. Unionville, CT, USA: S. Karger
Publishers, Inc; 2013.
7. Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrrison H, Jones L, Masic D,
Ptel B, Rowe J, Tallman M, Golstone AH, Fielding AK, Harrison C: IGH@
translocations, CRLF2 deregulation, and microdeletions in adolescents
and adults with acute lymphoblastic leukemia. J Clin Oncol 2012,
30:223100–223108.
8. Roll JD, Reutcher GW: CRLF2 And JAK2 in progenitor acute lymphoblastic
leukemia: a novel association in oncogenesis. Cancer Res 2010, 70:7347–7352.
9. Weigert O, Lane AA, Bir L, Kopp N, Chapuy B, Van Bodegom D, Toms AV,
Marubayashi S, Chistie AL, McKeown PRM, Bradner JE, Yoda A, Gaul C,
Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A,
Reignier CH, Erdmann D, Hofmann F, Eck M, Sallan SE, Levine RL, Kung AL,
Baffert F, Radimerski T, Weinstock DMJ: Genetic resistance to JAK2 enzymatic
inhibitors is overcome by HSP90 inhibition. J Exp Med 2012, 209(2):259–273.
10. Hood J, Doukas J, Martin M, Noronha G, Jamieson C, Soll R: TG101348, a
potent, highly selective JAK2 inhibitor, inhibits colony formation in stem
cells from polycythemia vera patients and prevents JAK2V617F-mediated
splenomegaly and death in a mouse model. J Clin Oncol 2007, 25:7031.
11. Muhammad F, Nikhil M, Byung L, Delong L: Dysregulation of JAK-STAT
pathway in hematological malignancies and JAK inhibitors for clinical
application. Biomarker Res 2013, 1:5.
12. Tirado CA, Lager J, Rosoff PM, et al: A case of infantile acute lymphoblastic
leukemia presenting with rearrangement of MLL at 11q23 and apparent
insertion or translocation at 10p12. Cancer Genet Cytogenet 2004, 154:57–59.
doi:10.1186/2050-7771-1-31
Cite this article as: Tirado et al.: A case of pediatric B-Lymphoblastic
leukemia presenting with a t(9;12)(p24;q11.2) involving JAK2 and
concomitant MLL rearrangement with apparent insertion at 6q27. Biomarker
Research 2013 1:31.
